Psychedelics research company Champignon Brands SHRM SHRMF announced Friday it is acquiring AltMed Capital Corp.
Run by Dr. Roger McIntyre, AltMed has been operating a ketamine clinic, the Health Canada-approved Canadian Rapid Treatment Centre of Excellence (CRTCE), for more than 18 months now.
Dr. McIntyre is well known in his field, having published more than 600 articles. AltMed’s director, Pat McCutcheon, is the co-founder and CEO of MediPharm Labs LABS MEDIF.
Chatting with Benzinga, Dr. McIntyre said, "Our new corporation is the largest and most influential company in the world that integrates both research and development of ketamine and psychedelic medicines along with excellence in the multidisciplinary care of persons with mood and related disorders (e.g. PTSD, pain substance abuse)."
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!